三重再摄取抑制类抗抑郁药的研究进展和盐酸安舒法辛的发现
发布时间：2018-12-21 17:53
【摘要】：当前治疗抑郁症的主流药物有选择性5羟色胺(5-HT)摄取抑制剂(SSRIs)和5-HT、去甲肾上腺素(NE)双重再摄取抑制剂(SNRIs);临床使用过程中存在起效缓慢、快感缺乏、认知功能低下和性功能障碍等缺陷;临床前和临床研究显示,在SNRIs的基础上加入多巴胺(DA)摄取抑制的5-HT/NE/DA三重再摄取抑制剂(SNDRIs)能够改善目前药物存在的治疗缺陷。盐酸安舒法辛为一种全新的SNDRIs,通过不均衡抑制5-HT/NE/DA再摄取发挥抗抑郁作用,预期在临床应用上将具有起效快,改善患者快感缺乏和性功能障碍,增加认知、奖励激励驱动和目标导向行为等特点。
[Abstract]:The current mainstream drugs in the treatment of depression include selective serotonin (5-HT) uptake inhibitors (SSRIs) and 5-HTand norepinephrine (NE) dual reuptake inhibitor (SNRIs); There are some defects in clinical use, such as slow onset, lack of pleasure, low cognitive function and sexual dysfunction. Pre-clinical and clinical studies have shown that the addition of (SNDRIs), a triple reuptake inhibitor of 5-HT/NE/DA with dopamine (DA) uptake inhibition on the basis of SNRIs, can improve the current treatment defects. The antidepressant effect of ambrofaxine hydrochloride is a new kind of SNDRIs, which plays an antidepressant role through unbalanced inhibition of 5-HT/NE/DA reuptake. It is expected that it will take effect quickly in clinical application, improve the patients' pleasure deficiency and sexual dysfunction, and increase cognition. Incentive-driven and goal-oriented behavior and so on.
【作者单位】： 烟台大学药学院分子药理和药物评价省部共建教育部重点实验室;绿叶制药集团长效缓控释和靶向制剂企业国家重点实验室;
【基金】：国家“重大新药创制”科技重大专项(2013ZX09402201)
【分类号】：R749.4
本文编号：2389254
[Abstract]:The current mainstream drugs in the treatment of depression include selective serotonin (5-HT) uptake inhibitors (SSRIs) and 5-HTand norepinephrine (NE) dual reuptake inhibitor (SNRIs); There are some defects in clinical use, such as slow onset, lack of pleasure, low cognitive function and sexual dysfunction. Pre-clinical and clinical studies have shown that the addition of (SNDRIs), a triple reuptake inhibitor of 5-HT/NE/DA with dopamine (DA) uptake inhibition on the basis of SNRIs, can improve the current treatment defects. The antidepressant effect of ambrofaxine hydrochloride is a new kind of SNDRIs, which plays an antidepressant role through unbalanced inhibition of 5-HT/NE/DA reuptake. It is expected that it will take effect quickly in clinical application, improve the patients' pleasure deficiency and sexual dysfunction, and increase cognition. Incentive-driven and goal-oriented behavior and so on.
【作者单位】： 烟台大学药学院分子药理和药物评价省部共建教育部重点实验室;绿叶制药集团长效缓控释和靶向制剂企业国家重点实验室;
【基金】：国家“重大新药创制”科技重大专项(2013ZX09402201)
【分类号】：R749.4
【参考文献】
相关期刊论文 前1条
1 栗原雅直;叶惠珍;;抗抑郁药[J];国外医药.合成药.生化药.制剂分册;1986年03期
，本文编号：2389254
本文链接：https://www.wllwen.com/yixuelunwen/jsb/2389254.html
最近更新
教材专著
